Drugs / NC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02807142 | Mar 2016 → Feb 2018 | secondary syringomyelia | Puerta de Hierro University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NC 1 | “All patients will be treated with NC1” NCT02807142 ↗1“Biological: NC 1 cell therapy” NCT02807142 ↗ |
| Modality | Cell therapy | “cell therapy NC1 administered via intrathecal” NCT02807142 ↗ |
| Route | Intrathecal | “administered via intrathecal” NCT02807142 ↗ |